BioArctic AB (publ)

OM:BIOA B Stock Report

Market Cap: SEK 19.6b

BioArctic Valuation

Is BIOA B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIOA B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 36.86
Fair Value
507.1% overvalued intrinsic discount
5
Number of Analysts

Below Fair Value: BIOA B (SEK223.8) is trading above our estimate of fair value (SEK36.86)

Significantly Below Fair Value: BIOA B is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIOA B?

Key metric: As BIOA B barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for BIOA B. This is calculated by dividing BIOA B's market cap by their current book value.
What is BIOA B's PB Ratio?
PB Ratio21.5x
BookSEK 918.63m
Market CapSEK 19.62b

Price to Book Ratio vs Peers

How does BIOA B's PB Ratio compare to its peers?

The above table shows the PB ratio for BIOA B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average12.1x
BONEX Bonesupport Holding
35.6x72.5%SEK 23.9b
BIOG B BioGaia
8.1x16.3%SEK 13.2b
VITR Vitrolife
2.1x18.8%SEK 29.6b
SOBI Swedish Orphan Biovitrum
2.7x16.4%SEK 113.5b
BIOA B BioArctic
21.5x49.7%SEK 19.8b

Price-To-Book vs Peers: BIOA B is expensive based on its Price-To-Book Ratio (21.5x) compared to the peer average (12.1x).

Price to Book Ratio vs Industry

How does BIOA B's PB Ratio compare vs other companies in the SE Biotechs Industry?

11 CompaniesPrice / BookEstimated GrowthMarket Cap
IMMU Mendus
0.5x-15.3%US$34.16m
IVACC Intervacc
0.4x26.6%US$6.54m
COMBI CombiGene
0.5xn/aUS$4.26m
SCOL Scandion Oncology
0.3x69.7%US$1.10m
BIOA B 21.5xIndustry Avg. 2.8xNo. of Companies11PB02.44.87.29.612+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: BIOA B is expensive based on its Price-To-Book Ratio (21.5x) compared to the Swedish Biotechs industry average (2.8x).

Price to Book Ratio vs Fair Ratio

What is BIOA B's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIOA B PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio21.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BIOA B's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BIOA B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 223.80
SEK 326.80
+46.0%
4.7%SEK 350.00SEK 310.00n/a5
Jan ’26SEK 199.50
SEK 322.00
+61.4%
6.5%SEK 350.00SEK 292.00n/a5
Dec ’25SEK 193.10
SEK 322.00
+66.8%
6.5%SEK 350.00SEK 292.00n/a5
Nov ’25SEK 143.40
SEK 292.20
+103.8%
8.5%SEK 340.00SEK 270.00n/a5
Oct ’25SEK 157.10
SEK 290.60
+85.0%
8.8%SEK 340.00SEK 270.00n/a5
Sep ’25SEK 166.50
SEK 290.60
+74.5%
8.8%SEK 340.00SEK 270.00n/a5
Aug ’25SEK 166.50
SEK 336.40
+102.0%
8.1%SEK 370.00SEK 290.00n/a5
Jul ’25SEK 235.40
SEK 368.00
+56.3%
11.8%SEK 450.00SEK 325.00n/a5
Jun ’25SEK 242.60
SEK 368.00
+51.7%
11.8%SEK 450.00SEK 325.00n/a5
May ’25SEK 195.00
SEK 366.20
+87.8%
12.2%SEK 450.00SEK 325.00n/a5
Apr ’25SEK 215.40
SEK 366.20
+70.0%
12.2%SEK 450.00SEK 325.00n/a5
Mar ’25SEK 219.20
SEK 365.20
+66.6%
12.2%SEK 450.00SEK 325.00n/a5
Feb ’25SEK 218.00
SEK 376.40
+72.7%
8.8%SEK 440.00SEK 342.00SEK 220.605
Jan ’25SEK 267.80
SEK 369.33
+37.9%
11.1%SEK 450.00SEK 312.00SEK 199.506
Dec ’24SEK 231.80
SEK 372.40
+60.7%
11.9%SEK 450.00SEK 312.00SEK 193.105
Nov ’24SEK 221.20
SEK 392.00
+77.2%
8.8%SEK 450.00SEK 356.00SEK 143.405
Oct ’24SEK 283.00
SEK 392.00
+38.5%
8.8%SEK 450.00SEK 356.00SEK 157.105
Sep ’24SEK 314.40
SEK 392.00
+24.7%
8.8%SEK 450.00SEK 356.00SEK 166.505
Aug ’24SEK 298.80
SEK 392.00
+31.2%
8.8%SEK 450.00SEK 356.00SEK 166.505
Jul ’24SEK 282.00
SEK 395.20
+40.1%
10.6%SEK 460.00SEK 356.00SEK 235.405
Jun ’24SEK 326.20
SEK 395.20
+21.2%
10.6%SEK 460.00SEK 356.00SEK 242.605
May ’24SEK 264.40
SEK 395.20
+49.5%
10.6%SEK 460.00SEK 356.00SEK 195.005
Apr ’24SEK 251.40
SEK 399.20
+58.8%
9.9%SEK 460.00SEK 356.00SEK 215.405
Mar ’24SEK 298.20
SEK 399.20
+33.9%
9.9%SEK 460.00SEK 356.00SEK 219.205
Feb ’24SEK 311.40
SEK 367.80
+18.1%
22.5%SEK 460.00SEK 220.00SEK 218.005
Analyst Price Target
Consensus Narrative from 5 Analysts
SEK 326.80
Fair Value
31.5% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 18:54
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioArctic AB (publ) is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB
Patrik LingDNB Markets
Rajan SharmaGoldman Sachs